SAFE vs Convertible Notes: The Conversion Mechanics Problem Founders Ignore

# SAFE vs Convertible Notes: The Conversion Mechanics Problem Founders Ignore

When we work with early-stage founders on seed funding, the conversation usually starts with a false choice: "Should we raise on a SAFE or a convertible note?"

Most advice you'll read focuses on surface-level differences—SAFEs are simpler, convertible notes have interest rates, SAFEs don't have maturity dates. True enough. But our clients who struggle most aren't confused about these mechanics. They're blindsided by what happens *when* these instruments convert, and how that conversion event shapes their actual founder dilution.

The problem is this: founders optimize for the immediate fundraising decision without modeling the downstream conversion scenario. And by the time conversion happens—usually during Series A or a down round—it's too late to change the terms that actually matter.

Let's talk about the conversion mechanics that nobody explains clearly, and why they matter more than you think.

## The Conversion Mechanics Gap: Why Simplicity Can Cost You Equity

Here's what most founders understand: SAFEs and convertible notes both eventually convert to equity at a discount or valuation cap. The conversion happens at your next qualified financing round (usually Series A).

Here's what most founders *don't* understand: the conversion mechanics differ in ways that create material differences in your dilution, and those differences are baked into your cap table before you've raised significant money.

### How Convertible Notes Convert (The Traditional Mechanics)

With a convertible note, the conversion formula is straightforward:

**Conversion Price = Most Favorable Of:**
- Series A price × (1 - discount rate) [typically 20-30% discount]
- Series A valuation cap ÷ fully diluted shares outstanding

Let's model a real scenario we've seen:

You raise $500K on a convertible note with:
- 20% discount
- $4M valuation cap
- 6% annual interest rate

Fast forward 18 months to Series A. Your Series A comes in at $10M post-money valuation.

The note converts using the better of these two options:
1. $10M × (1 - 0.20) = $8M effective valuation (the discount path)
2. $4M cap ÷ fully diluted shares = $X per share (the cap path)

Assuming the cap is more favorable, you've just locked in a conversion at your $4M valuation cap—even though you're raising at $10M. The investor who put in $500K at $4M cap is getting equity as if they invested at $4M, not $10M.

What's critical: that investor's shares are already sitting on your cap table. Interest accrued ($500K × 0.06 × 1.5 = $45K) gets added to the principal before conversion, so they're converting $545K at that favorable cap price.

### How SAFEs Convert (The Valuation Gap You Miss)

SAFE conversion is *superficially* similar but structurally different:

**Conversion Multiplier = Most Favorable Of:**
- Post-money valuation cap ÷ conversion valuation cap [if this creates a better outcome]
- (1 - discount) × Series A price

But here's the mechanical difference that matters: SAFEs don't accrue interest, and the conversion happens on a *post-money* basis in ways that create timing complexity.

Let's use the same scenario:

You raise $500K on a SAFE with:
- 20% discount
- $4M valuation cap
- Post-money valuation cap assumption

Same Series A at $10M post-money.

The SAFE converts into shares such that the SAFE holder's ownership percentage equals:

$500K ÷ $4M = 12.5% of the fully diluted cap table post-conversion.

This is fundamentally different than the convertible note. You're not converting at a price per share—you're converting into a *percentage ownership* of the post-Series A cap table.

If the Series A investor wants 25% and you have $500K in SAFEs outstanding, the math gets complex: the Series A dilution, the SAFE dilution, and your founder dilution all interact in ways that aren't immediately obvious.

## The Real Problem: The Valuation Cap Assumption Mismatch

Here's where we see founders get hurt.

You negotiate your seed valuation cap thinking it's a "ceiling" on your risk. You get a $5M cap, thinking "I'll only give up X% if we're worth more than $5M at Series A."

But the cap isn't a ceiling on your dilution—it's a *baseline* for conversion. The dilution you experience depends entirely on what happens between seed and Series A.

**Scenario 1: Up Round (What Founders Expect)**

You raise seed at $5M cap, Series A at $20M post-money.

- Convertible note: converts at $5M cap—great deal for investor, you save equity
- SAFE: converts into $500K ÷ $5M = 10% of the resulting cap table

You feel good. You got the cap, the Series A is strong, dilution is reasonable.

**Scenario 2: Flat Round (What Actually Happens)**

You raise seed at $5M cap, Series A at $5.5M post-money (down round dynamics).

- Convertible note: converts at $5M cap—investor gets a *better* deal than early Series A investors because they converted at the old cap
- SAFE: converts into $500K ÷ $5M = 10% of the resulting cap table, but now that cap table is much smaller

Your founder dilution from that seed round isn't 5-7%. It's 10% plus the Series A dilution. And you can't redo those terms.

This is the problem we see constantly: founders optimize for the valuation cap number ($5M sounds good!) without modeling *what that cap means in different Series A scenarios*.

## The Conversion Timing Trap: When Mechanics Create Surprises

Beyond the valuation mechanics, the *timing* of conversion creates problems in both instruments.

### The SAFE Stacking Problem

You raise multiple SAFE tranches across 12 months:
- Tranche 1 (Month 1): $250K at $4M cap, 20% discount
- Tranche 2 (Month 6): $250K at $5M cap, 20% discount
- Tranche 3 (Month 11): $250K at $6M cap, 20% discount

All three convert in the same Series A event at $10M post-money.

They don't convert at uniform terms—each converts at its own valuation cap and discount. Now your Series A documents need to carve out separate pro-rata rights, different ownership percentages, and different anti-dilution mechanics for each tranche. This creates complexity that's *invisible* until conversion actually happens.

Convertible notes have the same stacking problem, but with an additional complication: interest accrual. That early tranche from Month 1? It's accrued 10 months of interest by conversion. Now your Series A documents need to handle different principal amounts for different tranches, which changes the effective price each investor got.

We've seen founders discover these mechanics for the first time during Series A legal docs. By then, you're paying lawyers $10K-$20K to sort it out, and you can't change the underlying terms.

### The Conversion Valuation Mismatch

Here's a subtlety that catches people: if you're raising SAFE at a post-money valuation cap and Series A on a pre-money basis (or vice versa), the conversion math breaks.

You raise $1M SAFE at $5M *post-money* cap.
Series A: $3M check on $10M *pre-money*.

That post-money SAFE cap isn't directly comparable to pre-money Series A pricing. The conversion documents need to explicitly reconcile this, which means legal bills and potential disputes about what the intended terms were.

## The Hidden Cost: Interest vs. No Interest

This is straightforward but often underappreciated.

Convertible notes accrue interest. By the time you hit Series A, that $500K note has grown to $545K or more. In a flat or down market, that extra $45K of accrued interest can be material—it's additional dilution the founder wasn't expecting.

SAFEs don't accrue interest, so there's no hidden growth in principal. What you raised is what converts.

But SAFEs also don't have maturity dates, which means they can sit on your cap table indefinitely if you never hit a qualified financing. We had a client with a $250K SAFE that never converted because they bootstrapped to profitability without raising Series A. That SAFE holder had an indefinite claim on equity, which created issues years later when we exited.

Convertible notes expire (typically in 3-7 years). If conversion doesn't happen before maturity, the note either converts to equity or must be repaid in cash. For a bootstrapped or slow-growth company, this creates forced conversion mechanics that SAFEs avoid.

## What Actually Matters: The Modeling You Need to Do

Instead of debating SAFE vs. convertible notes in abstract terms, our process with founders is:

1. **Model multiple Series A scenarios**
- Scenario 1: Up round at $15M post-money
- Scenario 2: Flat round at $6M post-money
- Scenario 3: Down round at $3M post-money
- For each, calculate your founder dilution under both SAFE and convertible terms

2. **Calculate true conversion cost across multiple tranches**
- If you're raising seed over 6+ months, model stacked SAFEs/notes with different caps
- Show what your cap table actually looks like at Series A conversion

3. **Stress-test the valuation cap assumption**
- Your Series A pricing isn't predetermined. A $4M seed cap might be 2x or 10x lower than Series A pricing
- Show the founder dilution curve: how dilution changes as Series A valuation varies

4. **Account for maturity and interest accrual**
- If using convertible notes, show what accrued interest does to conversion price
- If using SAFEs, model what happens if conversion never occurs

We've found that founders who work through this modeling almost always have stronger negotiating positions—not because they change their instrument choice, but because they understand which terms actually matter.

## The Series A Preparation Imperative

Conversion mechanics matter most when you're [preparing for Series A](/blog/series-a-preparation-the-investor-diligence-acceleration-trap/). By then, your seed terms are locked. But if you understand these mechanics early, you can make better decisions about:

- What valuation cap to accept
- Whether discounts matter more than caps
- How much seed you should raise before hitting diminishing returns
- What cap table complexity you're creating

During Series A, your investors will model these scenarios precisely. They'll understand what each SAFE or note is truly costing them. The founders who survive due diligence without surprises are the ones who understood this math before signing seed docs.

## The Bottom Line

The choice between SAFE and convertible notes matters less than understanding what each choice *converts into* under different financing scenarios.

Most founders pick the instrument that feels simpler (SAFEs are marketed as simpler, and they are—on the surface). But simplicity doesn't buy you protection; understanding conversion mechanics does.

Before you finalize your seed terms, run the model. Show your cap table at Series A conversion across three scenarios. Understand what your valuation cap actually costs in a flat market. If you do this work upfront, the Series A is just an execution step. If you don't, conversion becomes a surprise.

That surprise is expensive.

---

The mechanics we've outlined here are part of broader [Series A financial operations](/blog/series-a-financial-operations-the-compliance-controls-framework-nobody-builds/) challenges that extend beyond just SAFE vs. convertible notes. Understanding how your cap table will flow through Series A—and what financial controls you need in place—is worth modeling now, not discovering later.

If you're raising seed capital and want to model these scenarios before committing to terms, [Inflection CFO offers a free financial audit](/blog/) that includes cap table modeling and Series A conversion analysis. We'll walk you through these mechanics with your actual numbers, so you see exactly what each term choice costs.